VivoSeq
Other

Angiogenesis

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Angiogenesis is an early-stage landscape with 0 programs across 2 companies. The most active players are XyloCor Therapeutics, Inc., Beijing Northland Biotech. Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

X

XyloCor Therapeutics, Inc.

0 programs

PreclinicalB

Beijing Northland Biotech. Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

19

clinical trials

Completed9 · 47%
Unknown status5 · 26%
Terminated3 · 16%
Not yet recruiting1 · 5%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

19 trials

Multiple Micronutrients Supplementation on Angiogenesis and Vasculogenesis Factors, and Fetal Biometry
Active, not recruiting·—·N/A·NCT06929793·200 enrolled
Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG
Not yet recruiting·XXyloCor Therapeutics, Inc.·Phase 2·NCT07118449·116 enrolled
Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)
Completed·TTexas Heart Institute·Phase 1·NCT00314366·21 enrolled
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
Completed·UUniversity of Arkansas·Phase 2·NCT00083382·83 enrolled
Effect of GLP-1 on Angiogenesis
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT02686177·50 enrolled
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
Completed·GGE Healthcare·Phase 2·NCT00565721·33 enrolled
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis
Completed·—·Phase 2·NCT03445884·42 enrolled
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Completed·—·Phase 1/2·NCT01806675·25 enrolled
The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy
Completed·UUniversity of Vermont·Phase 1·NCT00727948·11 enrolled
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
Completed·UUniversity of Arkansas·Phase 2·NCT00083408·20 enrolled
Treatment of PAD by Platelet Lysate for Therapeutic Angiogenesis
Completed·UUniversity of Jordan·Phase 1/2·NCT02941419·10 enrolled
68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis
Terminated·UUniversity of Lausanne Hospitals·Phase 1·NCT02666547·42 enrolled
RGD-PET-CT in Cancer Angiogenesis
Terminated·OOxford University Hospitals NHS Trust·Phase 2·NCT01492192·10 enrolled
Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
Terminated·UUniversity of Wisconsin, Madison·Phase 2·NCT03387514·5 enrolled
Effects of Local Insulin on Wound Angiogenesis
Unknown status·HHospital Central "Dr. Ignacio Morones Prieto"·Phase 3·NCT02396888·20 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)